Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability (2021 - 2024)

Xeris Biopharma Holdings' Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at $6.1 million for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Deferred Tax Liability fell 70.23% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Dec 2024, down 70.23%, and an annual FY2024 reading of $6.1 million, down 70.23% over the prior year.
  • Non-Current Deferred Tax Liability for Q4 2024 was $6.1 million at Xeris Biopharma Holdings, up from $3.3 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $20.5 million in Q4 2023, with the low at $2.5 million in Q3 2023.
  • Average Non-Current Deferred Tax Liability over 4 years is $5.2 million, with a median of $3.7 million recorded in 2022.
  • Year-over-year, Non-Current Deferred Tax Liability soared 463.31% in 2023 and then plummeted 70.23% in 2024.
  • Tracing XERS's Non-Current Deferred Tax Liability over 4 years: stood at $4.9 million in 2021, then dropped by 26.49% to $3.6 million in 2022, then soared by 463.31% to $20.5 million in 2023, then plummeted by 70.23% to $6.1 million in 2024.
  • Per Business Quant, the three most recent readings for XERS's Non-Current Deferred Tax Liability are $6.1 million (Q4 2024), $3.3 million (Q2 2024), and $2.6 million (Q1 2024).